Jefferies Financial Group’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-8,615
Closed -$99.1K 1788
2025
Q4
$99.1K Hold
8,615
﹤0.01% 1702
2025
Q3
$209K Hold
8,615
﹤0.01% 1268
2025
Q2
$142K Hold
8,615
﹤0.01% 1157
2025
Q1
$157K Hold
8,615
﹤0.01% 1424
2024
Q4
$320K Hold
8,615
﹤0.01% 1245
2024
Q3
$276K Hold
8,615
﹤0.01% 1142
2024
Q2
$707K Buy
8,615
+1,650
+24% +$178K 0.01% 855
2024
Q1
$1.01M Buy
6,965
+5,800
+498% +$490K 0.01% 823
2023
Q4
$107K Sell
1,165
-437
-27% -$44.4K ﹤0.01% 1540
2023
Q3
$264K Buy
+1,602
New +$208K ﹤0.01% 1262

Other funds holding CDLX

Jefferies Financial Group's CDLX Position: Q1 2026 in Review

Jefferies Financial Group sold out of Cardlytics (CDLX) in Q1 2026, closing a stake of 8,615 shares — an estimated $99.1K sold.

Jefferies Financial Group first reported a position in CDLX in Q3 2023 and held it in 10 quarters. The position peaked at $1.01M in Q1 2024. 58 funds tracked by Wall St. Rank hold CDLX as of Q1 2026.

  • Jefferies Financial Group reported no remaining Cardlytics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 8,615 Cardlytics shares in Q1 2026, an estimated $99.1K.
  • Jefferies Financial Group first reported a position in Cardlytics in Q3 2023 and held it in 10 quarters.
  • Jefferies Financial Group's Cardlytics position peaked at $1.01M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Cardlytics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.